CLINICAL_TRIALS
trial_result
· 2026-02-12
Clinical Trial Update: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia [Phase 2]
Summary
This Phase 2 trial evaluating inotuzumab ozogamicin in children with MRD-positive CD22+ acute lymphoblastic leukemia was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: St. Jude Children's Research Hospital | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED